Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning (Q57830334)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

author name string

Marta Cremonesi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Mahila Esmeralda Ferrari

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Lisa Bodei

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Carlo Chiesa

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Anna Sarnelli

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Cristina Garibaldi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Massimiliano Pacilio

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Lidia Strigari

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Roberto Orecchia

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Chiara Maria Grana

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Francesca Botta

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

publication date

21 May 2018

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

number of pages

16

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

45

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

2426-2441

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

https://scigraph.springernature.com/pub.10.1007/s00259-018-4044-x

0 references

Tolerance of normal tissue to therapeutic irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-rate effects in targeted radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry for treatment with radiolabelled somatostatin analogues. A review.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of normal tissue complication probability models in the clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation-associated kidney injury.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kidney dosimetry in ¹⁷⁷Lu and ⁹⁰Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method, and risk factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy-related hematological malignancies after peptide receptor radionuclide therapy with (177)Lu-DOTA-Octreotate: Incidence, course & predicting factors in patients with GEP-NETs

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?

1 reference

https://pubmed.ncbi.nlm.nih.gov/29785514

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-018-4044-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29785514%20AND%20SRC:MED&resulttype=core&format=json

27 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57830334&oldid=1807004840"